Calcipotriol/Betamethasone Dipropionate Foam
Effective topical foam treatment for plaque psoriasis in adults, combining vitamin D analogue and corticosteroid for symptom relief.
Introduction
Psoriasis is a chronic autoimmune skin disorder characterised by well-defined red, scaly plaques on the skin due to rapid turnover of skin cells and inflammation. Plaque psoriasis, the most common form, affects millions worldwide and can significantly impact quality of life through itching, pain, and visible lesions.
Calcipotriol/betamethasone dipropionate foam, marketed as Enstilar®, is a prescription topical medication approved for adults 18 years and older with plaque psoriasis. This alcohol-free foam in a pressurised spray allows easy application over large body areas, unlike traditional ointments or gels. Approved by regulatory bodies including the US FDA, European Union, Canada, Australia, and New Zealand, it contains calcipotriol 50µg/g and betamethasone dipropionate 0.5mg/g.
The fixed-dose combination leverages synergistic effects: calcipotriol, a synthetic vitamin D3 analogue, normalises skin cell growth, while betamethasone dipropionate, a potent corticosteroid, reduces inflammation, relieving symptoms like burning, pain, itching, and swelling. Clinical trials demonstrate superior efficacy over individual components or other formulations like ointments and gels for body psoriasis.
How it works
The foam combines the pharmacological actions of two active ingredients studied both independently and together. Calcipotriol hydrate is a synthetic vitamin D3 analogue that binds to vitamin D receptors, inhibiting keratinocyte proliferation, promoting differentiation, and suppressing inflammatory cytokines in psoriatic skin.
Betamethasone dipropionate, a Group III potent topical corticosteroid, exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by activating glucocorticoid receptors, reducing cytokine production, and modulating immune responses.
Together, they provide rapid symptom relief and lesion clearance. Each gram of foam delivers 52.2 mcg calcipotriol hydrate (equivalent to 50 mcg calcipotriol) and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone). The foam vehicle enhances penetration and tolerability, with stability maintained for up to 2 years at room temperature.
In randomised trials, 4 weeks of once-daily use achieved treatment success (clear/almost clear skin on trunk/limbs) in greater proportions than vehicle, monotherapies, or ointment equivalents. It also improved modified Psoriasis Area and Severity Index (PASI) scores, itch-related sleep loss, and health-related quality of life more effectively.
How to use
Enstilar foam is for external topical use only. Shake the can well before use. Apply a thin layer once daily to affected areas (trunk, limbs) for up to 4 weeks, or until clear. Maximum dose: 60g (two cans) every 4 days. Wash hands after application.
- Avoid face, scalp (unless directed), groin, axillae, or skin folds.
- Do not cover with bandages unless advised.
- For maintenance after initial success: apply twice weekly to prevent relapse, as shown in PSO-LONG trial where proactive use prolonged remission.
- Prime can if new or unused for 2+ days: spray 5 times away from skin.
- Store at room temperature; do not expose to heat >50°C.
US FDA approves for patients 12+ years; other regions 18+. Case studies confirm long-term (up to 12 months) proactive efficacy with good tolerability.
Contraindications
Do not use if hypersensitive to calcipotriol, betamethasone, or excipients. Contraindicated in:
- Generalised pustular or erythrodermic psoriasis.
- Acute exacerbations of psoriasis.
- Skin infections (bacterial, viral, fungal).
- Perioral dermatitis, acne vulgaris, rosacea.
- Face, groin, axillae if atrophy present.
Not for oral, ophthalmic, or intravaginal use.
Warnings and precautions
Inform physician if hypercalcaemia, hypercalciuria, renal impairment, or disorders of calcium metabolism. Monitor calcium levels if doses exceeded; discontinue if elevated until normalised. Hypercalcaemia risk increases beyond 4 weeks, though not fully evaluated.
Avoid excessive use to prevent systemic corticosteroid effects like HPA axis suppression (rare in trials). Possible skin atrophy, striae with prolonged use. Discontinue if irritation worsens.
In trials, no clinically relevant calcium homeostasis or HPA axis effects. Application-site events mild/moderate.
| Precaution | Details |
|---|---|
| Calcium monitoring | Check if symptoms of hypercalcaemia (nausea, fatigue) |
| Skin thinning | Monitor treated areas; taper if prolonged |
| Phototoxicity | Sunscreen; avoid sun exposure |
Use in specific populations
- Pregnancy: Category C; use only if benefit outweighs risk. Topical absorption minimal.
- Breastfeeding: Caution; avoid breast application. Systemic absorption low.
- Pediatrics: FDA-approved 12+ years; mean weekly dose 47g showed no quantifiable systemic levels in moderate psoriasis.
- Elderly: No overall safety/efficacy differences; limited >65 data.
- Renal/Hepatic impairment: No specific studies; caution advised.
Trials showed consistent efficacy across ages.
Potential drug interactions
No formal studies, but avoid concomitant use with agents raising serum calcium (e.g., calcium supplements, vitamin D, thiazides, some antacids). May potentiate topical corticosteroids’ effects.
Side effects
Mostly mild/moderate application-site reactions: erythema, pruritus, pain (up to 7%). Rare: folliculitis, skin atrophy, hypercalcaemia (<1%). No serious systemic effects in trials.
| Common (>1/100) | Uncommon (1/1000-1/100) |
|---|---|
| Itching, rash, redness | Folliculitis, dryness |
| Burning sensation | Pustular eruptions |
Long-term proactive use well-tolerated in case reports up to 12 months.
Frequently Asked Questions
Q: How quickly does Enstilar foam work?
A: Significant improvement often within 3-7 days; full clearance by 4 weeks in responders.
Q: Can it be used on the scalp?
A: Not recommended; other formulations like gel preferred for scalp.
Q: Is maintenance therapy effective?
A: Yes, twice-weekly application post-induction reduces relapses per PSO-LONG trial.
Q: What if I overuse it?
A: Risk of hypercalcaemia; stop and consult physician for calcium checks.
Q: Is it safe for long-term use?
A: Proactive up to 52 weeks safe in studies; monitor skin.
References
- Calcipotriol/Betamethasone Dipropionate Foam: A Review — Kim de ES et al. Drugs. 2016-10-12. https://pubmed.ncbi.nlm.nih.gov/27663245/
- Calcipotriol/betamethasone dipropionate foam — DermNet NZ. Recent access. https://dermnetnz.org/topics/calcipotriolbetamethasone-dipropionate-foam
- Calcipotriol/betamethasone foam for proactive management of plaque psoriasis — Drugs in Context. 2020. https://www.drugsincontext.com/calcipotriol-betamethasone-foam-for-proactive-management-of-plaque-psoriasis-four-case-reports/
- Calcipotriol-betamethasone-dipropionate-formulations-for-psoriasis — Megna M et al. 2020-09. https://www.italianskinconsulting.it/wp-content/uploads/2021/09/Calcipotriol-betamethasone-dipropionate-formulations-for-psoriasis-an-overview-of-the-options-and-efficacy-data-MEGNA-2020.pdf
- Enstilar FDA Label — US FDA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207589s005s006s007lbl.pdf
Similar Articles
Read full bio of medha deb
